Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Greenberg

Podiatrist, Foot Surgery New York, NY Doctor of Podiatric Medicine

NPI 1134123110 CMS profile 232851

101 W 79Th St, New York, NY 10024

Open in the dashboard

General payments

$4,347

65 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Greenberg of New York, NY is reported in the CMS Open Payments database as having received $4,347 across 65 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $425 11
2024 General $337 7
2023 General $628 10
2022 General $568 10
2021 General $754 15
2020 General $1,332 5
2019 General $303 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Greenberg
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Paul Greenberg were reported at $425. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Paul Greenberg Podiatrist, Foot Surgery median Middle half National median
2019 $303 $167 $67–$484 $163
2020 $1,332 $114 $40–$323 $114
2021 $754 $171 $57–$502 $132
2022 $568 $196 $66–$556 $149
2023 $628 $187 $78–$466 $160
2024 $337 $190 $78–$557 $164
2025 $425 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gotham Surgical Solutions & Devices, Inc. $1,275 3 payments
  2. Treace Medical Concepts, Inc. $663 14 payments
  3. Stryker Corporation $542 10 payments
  4. DePuy Synthes Sales Inc. $369 8 payments
  5. Extremity Medical $200 1 payment
  6. Arteriocyte Medical Systems, Inc. $173 1 payment
  7. Abbott Laboratories $155 1 payment
  8. MedShape, Inc. $145 1 payment
  9. Djo, LLC $145 3 payments
  10. Nevro Corp. $115 1 payment
  11. Other $568 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,108 64 payments
  2. Education $1,239 1 payment
Products named General payments · program years 2019–2025
  1. IO FiX $200 1 payment
  2. MOTOBAND $190 4 payments
  3. LAPIPLASTY SYSTEM Foot And Ankle $187 5 payments
  4. Magellan $173 1 payment
  5. Supera peripheral stent system $155 1 payment
  6. CLAW II $154 1 payment
  7. AUGMENT INJECTABLE $154 1 payment
  8. Hammerlock $151 2 payments
  9. Lapiplasty System Y $146 2 payments
  10. DynaClip Bone Fixation System, Quattro, 22mm x 20mm x 20mm $145 1 payment
  11. Other $2,220 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

128

Median for Podiatry: 160

Drug cost

$2,137

Median for Podiatry: $2,368

Branded share of claims

11.7%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Econazole Nitrate Generic 68 $1,518
Ketoconazole Generic 22 $296
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 15 $217
Meloxicam Generic 23 $106

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$102,613

Of which drugs: $666

Medicare patients

694

Average age 75

Services billed

1,344

472 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 67%
High blood pressure 52%
Osteoporosis 32%
Ischemic heart disease 27%
Diabetes 19%
Cancer 19%
Depression 17%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 26 115 $628
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 44 $35
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 17 43 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record